Perseus Proteomics Inc.

4882

TSE PrimePharmaceuticals

¥ -

You can review earnings summary, quarterly trends, full-year progress, and detailed income statement data.

descriptionIncome Statement (PL) Summary

Updated: 2026-08-13FY2027 Q1

Revenue

1.5100M JPY

YoY +19.7%

Operating Income

-2100M JPY

YoY +6.4%

Net Income

-7.4100M JPY

YoY +13.6%

EPS

-11.8JPY

YoY +0.8%

Performance Trend

Revenue, operating income and net income trend (last 5 periods)

RevenueOperatingNet Income

1.4億円

-1.7億円

-4.8億円

-7.9億円

-11億円

Rev: 71.9百万円Op: -4.7億円NI: -6億円

Rev: 94.2百万円Op: -7億円NI: -7.9億円

Rev: 1億円Op: -8.9億円NI: -11億円

Rev: 1.2億円Op: -8.3億円NI: -9億円

Rev: 1.4億円Op: -7.4億円NI: -7.2億円

2022/FY2023/FY2024/FY2025/FY2026/FY

Full-Year Progress

FY2027 Q1

Net Income-

Revenue Progress35M

Revenue Forecast-

Net Income Progress-

Net Income Forecast-

Income Statement Details

Unit: JPY

Unlock Long-Term Financial Data

Your current plan allows viewing financial data for the latest 1 year (annual only). Upgrade to the Standard Plan to view up to 3 years (including quarterly data), or the Premium Plan to access all historical data.

Standard Plan Premium Plan